Kajian klinikal Migrain di Minnesota
7 kajian untuk Migrain sedang mencari peserta di lokasi di Minnesota.
Bandar di Minnesota
Teks kajian rasmi (Bahasa Inggeris)
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- Clinical Research Institute, Minneapolis
Mengambil pesertaFasa 1
Umur 6 hingga 11 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06995729Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Clinical Research Institute, Minneapolis
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05156398Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Brackenridge Outpatient Research Pharmacy, Rochester
- Clinical Research Trials Unit, Rochester
- Mayo Clinic, Rochester
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04649242Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Mayo Clinic, Rochester
Mengambil pesertaFasa 4
Umur 18 hingga 70 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Minneapolis Clinic of Neurology - Burnsville /ID# 232551, Burnsville
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Clinical Research Institute, Minneapolis
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07645924Investigating Brain Function in People With and Without Visual Snow Syndrome Using Adaptation to Visual Stimuli
- University of Minnesota, Minneapolis
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 60 · Semua jantina · Dikemas kini 14 Jan 2026 · NCT06961864Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.